Get the Stockscreener App
18.03
6.77%
-1.31
After Hours:
18.02
-0.01
-0.06%
Vor Biopharma Inc stock is traded at $18.03, with a volume of 733.08K.
It is down -6.77% in the last 24 hours and down -17.86% over the past month.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
See More
Previous Close:
$19.34
Open:
$19.45
24h Volume:
733.08K
Relative Volume:
0.88
Market Cap:
$1.07B
Revenue:
Net Income/Loss:
$-883.08M
P/E Ratio:
-0.0541
EPS:
-333.4782
Net Cash Flow:
$-150.65M
1W Performance:
-9.40%
1M Performance:
-17.86%
6M Performance:
+20.44%
1Y Performance:
-37.96%
1-Day Range:
$18.00
$19.45
1-Week Range:
$18.00
$20.52
52-Week Range:
$6.50
$31.31
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
18.03 | 1.07B | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Jefferies | Buy |
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Form 4 Vor Biopharma Inc For: 5 October By Investing.com - Investing.com Canada
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Vor Biopharma (Nasdaq:VOR)Stock Analysis - Simply Wall Street
Jefferies Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $48 - moomoo.com
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com India
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com Canada
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com UK
VOR: Phase III MG trial enrollment complete; robust efficacy and market expansion plans underway - TradingView
Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Mar - GuruFocus
Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis - marketscreener.com
Vor Biopharma Inc. (VOR) Latest Press Releases & Corporate News - Yahoo Finance
Vor Biopharma (VOR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VOR - MarketBeat
Vor Biopharma Stock Price Forecast. Should You Buy VOR? - StockInvest.us
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - sg.finance.yahoo.com
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Vor Bio To Participate in Upcoming September Conferences - marketscreener.com
Vor Bio To Participate in Upcoming September Conferences - Yahoo Finance
Vor Biopharma Inc. (VOR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vor Biopharma (VOR) RA Capital-linked option yields 1,500 shares - Stock Titan
Why Did Vor Biopharma (VOR) Stock Drop After Its Latest Update? - Sahm
Vor (VOR) Snapshot: Adds 1.28% to Close at $23.36 on the Day; Key Range: Support at $22.19 and Resistance at $24.53 Frame the Range in the Latest ReadingHot Stock Picks - vinanet.vn
US and Canadian markets settled this week on a negative note, Two stocks to consider – LITH, VOR - kalkine.ca
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake - Stock Titan
Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership - Stock Titan
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright - MarketBeat
Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock - Stock Titan
Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18 - webull.com
VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00 - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings - MarketBeat
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma (VOR) Reports Improved Cash Position and Reduced L - GuruFocus
Vor Biopharma Reports Q2 2026 Financial Results in SEC Form 10-Q Filing - Kalkine Media
Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate - scanx.trade
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results - MarketBeat
Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations - GuruFocus
VOR Stock Update: Telitacicept Advances Amid Mixed Financial Sig - GuruFocus
Vor Biopharma Shares Drop After Q2 Results - marketscreener.com
Vor Biopharma Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs - TradingView
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vor Biopharma Inc Stock (VOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Aug 24 '26 |
Option Exercise |
3.74 |
1,500 |
5,604 |
1,500 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Jul 16 '26 |
Sale |
19.75 |
213 |
4,207 |
4,501,882 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 22 '26 |
Sale |
15.77 |
165,150 |
2,604,416 |
2,402,095 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 20 '26 |
Sale |
15.77 |
171,963 |
2,711,857 |
2,567,245 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 17 '26 |
Sale |
16.28 |
458,411 |
7,462,931 |
2,739,208 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 15 '26 |
Sale |
16.01 |
53,644 |
858,840 |
3,197,619 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 14 '26 |
Sale |
15.97 |
153,735 |
2,455,148 |
3,251,263 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 13 '26 |
Sale |
16.15 |
530,610 |
8,569,352 |
3,404,998 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 10 '26 |
Sale |
15.75 |
828 |
13,041 |
3,935,608 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 09 '26 |
Sale |
16.59 |
135,201 |
2,242,985 |
3,936,436 |
3.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):